雷珠单抗治疗视网膜中央静脉阻塞继发黄斑水肿的疗效观察

Clinical effect of Ranibizumab intravitreous injection for macular edema secondary to central retinal vein occlusion

目的 评价雷珠单抗（Ranibizumab）玻璃体腔注射治疗视网膜中央静脉阻塞（CRVO）继发黄斑水肿（ME）的疗效及安全性.方法 临床病例回顾性系列研究.对2012年8月至2013年12月在天津市眼科医院临床确诊的CRVO-ME患者40例40只眼,玻璃体腔注射Ranibizumab 0.5 mg治疗,于治疗前及治疗后1周、1个月、2个月、3个月、4个月、5个月、6个月行最佳矫正视力（BCVA）、眼压、裂隙灯、眼底镜、眼底照相及OCT检查.对比分析治疗前后BCVA及黄斑中心视网膜厚度（CMT）变化.结果 雷珠单抗治疗后所有访视期BCVA均有明显提高,与治疗前相比差异有统计学意义（P＜0.05）.治疗后2个月、3个月、5个月时CMT减少显著,与治疗前相比差异有统计学意义（P＜0.05）.治疗后1周和治疗后1个月、4个月、6个月时CMT均有减少,但与治疗前相比差异无统计学意义（P＞0.05）.相关性分析显示,BCVA与CMT呈显著负相关关系.访视期内未出现明显不良反应.结论 雷珠单抗玻璃体腔注射治疗CRVO-ME短期内疗效显著,安全可靠,无明显不良反应.

Objective To evaluate the efficiency and safety of intravitreous Ranibizumab injection for macular edema （ME） secondary to central retinal vein occlusion （CRVO）.Methods Forty patients （40 eyes） of CRVO were observed after Ranibizumab 0.5mg intravitreous injection.Before and after injection,best corrected visual acuity （BCVA）,intraocular pressure,slit lamp,ophthalmoscope,fundus photography and optical coherence tomography （OCT） were examined.Comparative analysis was proceeded about BCVA and central macular thickness （CMT） before and after treatments.Results All of BCVA after injection were evident improved.The differences had statistically significance.In 2,3,5 months after injection,CMTs were evident decreased,had statistically significance compared to before injection.In 1 week,1 month,4 and 6 months after injection,though CMT decreased,had no statistically significance compared to before injection.Correlation analysis displayed significant negative correlation between BCVA and CMT.All the patients showed no serious adverse reactions.Conclusions Intravitreal injection of Ranibizumab is effective and safe for therapy of ME secondary CRVO in short term,has no serious adverse reactions.